Cite

HARVARD Citation

    Juarez, M. et al. (2021). A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome. Rheumatology. pp. 1364-1375. [Online]. 
  
Back to record